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the treatment of uterine fibroids: a cohort study
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Background: This research investigates whether modifications to the magnetic resonance-guided focused
ultrasound ablation of uterine fibroid (MRgFUS) system used resulted in improved treatment volumes of uterine
fibroids, while maintaining safety.
Methods: This study is a prospective cohort analysis of 34 women undergoing the ExAblate 2100 MRgFUS
treatment for their uterine fibroids.
Results: The percentage of non-perfused volume (NPV) achieved with the ExAblate 2100 system was 54.92%
compared with 50.49 % with the ExAblate 2000 system over the preceding year (p = 0.543). The ExAblate 2100
system resulted in a greater NPV in hyper-intense fibroids compared with the ExAblate 200 system (43.20% versus
36.33%, p = 0.005). There have been no recorded hospital admissions, no skins burns, and no reported major
adverse events since the introduction of this new system.
Conclusion: Overall, the new system has thus far shown an encouraging safety record and an improvement in
non-perfused volumes achieved, especially in hyper-intense fibroids.
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Magnetic resonance-guided focused ultrasound (MRgFUS)
treatment of uterine fibroids uses MR guidance to direct
high-intensity focused ultrasound into a fibroid, resulting in
coagulative necrosis within the tissue. This treatment was
first performed in 2002 [1] and received approval from the
US Food and Drug Administration in 2004. It is known that
the signal intensity of the uterine fibroids (UF) at baseline
T2-weighted MR imaging and the non-perfused volume
(NPV) of the fibroid post-treatment are important determi-
nants of outcome following MRgFUS [2]. Compared to
other treatment options for uterine fibroids, focused ultra-
sound has been shown to carry a very low risk of complica-
tions and side effects [1]. At our institution, uterine fibroids* Correspondence: s.quinn@imperial.ac.uk
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reproduction in any medium, provided the orhave been treated using focused ultrasound since 2003. In
January 2011, a new transducer and software system, the
ExAblate 2100 (InSightec, Haifa, Israel), replaced the previ-
ous system in use, the ExAblate 2000 (InSightec).
The ExAblate 2100 system incorporates several soft-
ware and hardware upgrades which were not compo-
nents of the ExAblate 2000 system. This includes a new
3D axis ultrasound transducer, capable of rotation, tilt,
and movement in the vertical plane to allow the trans-
ducer to be placed much closer to the patient's skin sur-
face than formerly. The system also allows transducers
to be shut off in banks which allows for sculpting and
steering of the ultrasound beam. This affords the oper-
ator enhanced control in avoiding non-target structures
and defining the location of energy dissipation posterior
to the fibroid. As with the earlier system, focal spot size,
location, and angle, in addition to the exact amount of
energy deposited, can all be manually controlled usingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the precise location of treated tissue, providing the oper-
ator with a high degree of control throughout the pro-
cedure. In addition, the introduction of ‘scar tape’, an
adhesive barrier that prevents build-up of heat within
the scar tissue, reduces the risk of cutaneous thermal
injury for treating patients who have an anterior abdom-
inal wall scar [3]. This tape enables women with low
transverse abdominal scars to be treated safely while
avoiding the build-up of excess heat within the scar and
subsequent burns. This tape was not available to us
when we were treating patients with the ExAblate 2000
system; however, this could be used by other units using
the earlier system.
The overall effectiveness of MRgFUS has been linked
to the overall volume of fibroid tissue treated, as mea-
sured by the NPV [4]. The NPV refers to the volume of
fibroid tissue identified as non-enhancing following ad-
ministration of radio-opaque contrast agent.
We aimed to assess the effectiveness of this new technol-
ogy by comparing the non-perfused volumes achieved with
the newer technology to those obtained using the ExAblate
2000 system. We also aimed to compare the safety profile
of the two systems.
Methods
This was a prospective cohort study of women undergo-
ing treatment for uterine fibroids with the ExAblate
2100 MRgFUS system (n = 34). The results were com-
pared with a data collected retrospectively from a cohort
of women undergoing treatment using the ExAblate
2000 system prior to January 2011 (n = 238).
All patients underwent standard pelvic MRI including
T1 and T2 images prior to treatment. All MRI images
were reviewed by two independent investigators (SQ
and JV). The fibroids were graded as hypo-intense
or hyper-intense relative to myometrium and rectus
abdominus skeletal muscle. The non-perfused volume
following both systems was calculated using the same
software package utilizing the planimetric method (Re-
port Card Software, GE Healthcare, Milwaukee, USA)
using the images from the sagittal T2 images (5-mm
slices). Volume calculation between investigators was
tested for agreement using the Bland-Altman method
[5] and interclass correlation coefficient.
A range of patient demographic data was recorded,
including body mass index, symptom severity score, parity,
ethnicity, primary symptoms, and previous treatment.
Prospective data was collected for those women under-
going the newer ExAblate 2100 system for 1 year post-
treatment. All data regarding complications were recorded
via review of patients' notes, interview with patients at fol-
low up, telephone and written questionnaires, and direct
observations of patients' post-procedures.The statistical package SPSS version 20.0 (IBM, Armonk,
NY, USA) was used to analyze differences between va-
riables in both groups. Continuous data were tested for
normal distribution by Shapiro-Wilk test. Normally dis-
tributed data were tested using Student's t test; where
variables were not normally distributed, Mann–Whitney
test was performed to investigate differences between
these groups. For the categorical data of hyper-intensity,
the differences between those undergoing the ExAblate
2100 and 2000 systems were tested using chi-square
testing between these two groups.
The NPV achieved between the groups was inves-
tigated for the possible effect of signal intensity dif-
ferences between groups using Mann–Whitney non-
parametric testing. Analysis of covariance was used to
adjust for confounding effect of different signal inten-
sities of the fibroids treated. Differences in fibroid num-
bers and signal intensity between those undergoing the
ExAblate 2100 and 2000 systems were examined using
chi-square test. A p value less than 0.05 was taken to in-
dicate a significant difference between groups.
Results
The MR images and treatment details from 238 women
who had undergone treatment using the ExAblate 2000
system and 34 women undergoing treatment using the
ExAblate 2100 system were examined. Mean follow-up
from ExAblate 2000 patients was 3.81 years (SD 1.98).
ExAblate 2100 patients were followed up over the first
year post-treatment. The test for agreement of volume
calculation between investigators using the Bland-
Altman method [5] found a bias of 5.24 ml (SD 16.46)
and interclass correlation coefficient of 0.998. This de-
gree of agreement between the two investigators was
judged to be acceptable.
The demographics for the patient cohort are described
in Table 1, and pre-treatment clinical features for the
two groups are compared in Table 2.
The percentage NPV achieved with the ExAblate 2100
system was 54.92% (SD 19.28) compared with 43.72%
(SD 22.26) with the ExAblate 2000 system over the
whole 9 years, a significant difference (p = 0.007). When
signal intensity of the fibroids was corrected for diffe-
rences, the %NPV between the two treatments remained
statistically significant (p = 0.012). Of the women treated
by the ExAblate 2100 system, 17.6% had fibroids found
to be hyper-intense on T2-weighted MRI images, com-
pared with 28.2% of those undergoing treatment with
the ExAblate 2000 system (p = 0.137). The mean NPV
achieved in women with hyper-intense fibroids using the
ExAblate 2100 was 43.20% compared with 57.43% in
those women with hypo-intense UF. This compares fa-
vorably with the 36.33% NPV achieved in hyper-intense
UF treated with the ExAblate 2000 system.
Table 1 Demographics of subjects undergoing treatment with the ExAblate 2000 and 2100 systems
ExAblate 2000 (n = 238) ExAblate 2100 (n = 34) p Value
Age Mean years (range) 42.2 (25–84) 39.47 (25–52) 0.26a
BMI Mean (SD) 25.1 (4.6) 23.41 (3.79) 0.038a
Race White, N (%) 135 (48.0) 14 (41.18) 0.01b
Black, N (%) 76 (27.0) 12 (35.30) 0.01b
Asian, N (%) 18 (6.4) 8 (23.52) 0.01b
Arabic, N (%) 7 (2.5) 0 0.01b
Mixed, N (%) 4 (1.4) 0 0.01b
Parity Mean (SD) 0.51 (0.89) 0.38 (0.82) 0.328c
Symptom severity score Mean (SD) 62.64 (17.80) 61.71 (17.86) 0.841c
Hyper-intense fibroids N (%) 67 (28.2) 6 (17.6) 0.196b
Previous treatment N (%) 43 (15.4) 5 (13.9) 0.88b
Number of fibroids Mean (SD) 6.43 (6.54) 4.18 (3.85) 0.044c
Mean uterine volume ml (SD) 788.12 (408.01) 659.62 (259.91) 0.093c
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required a second treatment for their uterine fibroids in
order to complete the treatment. These second treat-
ments were done at 1, 2, and 7 months following the ini-
tial treatment and were deliberately planned as the
volume of fibroid tissue to be treated could not be
achieved in a single session.
The details of the ExAblate 2000 treatments by year
since 2003 are detailed in Table 3. When compared to the
NPVs initially achieved with the ExAblate 2000 system,
the NPV increased and reached a statistically significant
improvement by 2011 with the introduction of the
ExAblate 2100 system (p = 0.007). When compared to the
NPV achieved in recent years (2009 and 2010), the NPVs
are greater with the ExAblate 2100 system; however, this
did not reach statistical significance (p = 0.543).
Following the treatment of 34 women using the new
ExAblate 2100 system, there have been no recorded hos-
pital admissions, no skins burns, and no reported major
adverse events. All women were discharged from the
MRgFUS center within 3 h of their treatment, and only
one woman required analgesia to take home (diclofenacTable 2 Comparison between ExAblate 2000 and 2100 treatm
ExAblate 2000 system (
Mean volume of fibroids treated, ml (SD) 337.78 (252.75)
Mean NPV, ml (SD) 165.41 (136.39)
Mean percentage NPV (%) 43.72
% NPV in hypo-intense fibroids 46.79
% NPV in hyper-intense fibroids 36.33
NPV non-perfused volume.
aMann-Whitney test.orally for 3 days). There were no reported urinary tract
infections and no persistent neurological problems
or other complications. For patients treated with the
ExAblate 2000 system, minor complications were ex-
perienced by 4% of patients and included urinary tract
infection, urinary retention, PV bleeding, and transient
buttock pain. One woman experienced PV fibroid ex-
pulsion, there was one skin burn requiring a small
surgical intervention, and one case of a persistent neur-
opathy. No emergency hysterectomies were required
following MRgFUS therapy in either group.
Discussion
Magnetic resonance-guided focused ultrasound abla-
tion, through controlled deposition of high acoustic en-
ergy, causes thermally induced coagulative necrosis of
leiomyoma cells. The procedure is performed using
real-time MRI guidance, allowing the operator to pre-
cisely control the location, intensity, and size of the
focus of energy deposited. Control with MRI also allows
the operator to monitor the temperature of the tissue
treated. This technique has been in use at our institutionents






Table 3 ExAblate treatments in 2003–2011
Year Mean age,
years (SD)




Mean %NPV (SD) % HI
dominant fibroid
2003 41.97 (5.44) 24.95 (4.05) 64.79 (17.47) 809.73 (445.48) 333.8 (209.75) 41.22 (25.66) 29.2
2004 43.87 (5.09) 24.11 (3.17) 62.1 (14.05) 734.20 (323.86) 387.0 (198.31) 47.33 (23.21) 29.0
2005 43.67 (8.93) 27.23 (4.14) 78.12 (16.24) 949.51 (383.33) 544.23 (276.52) 33.4 (20.34) 30.8
2006 42.74 (10.20) 25.00 (4.39) 64.1 (19.13) 958.1 (469.46) 495.1 (291.49) 39.4 (24.31) 26.9
2007 42.25 (5.93) 26.10 (5.55) 59.4 (16.93) 828.65 (446.98) 431.7 (289.64) 40.7 (22.04) 32.0
2008 43.15 (6.97) 23.75 (3.08) 64.1 (19.26) 861.90 (469.25) 445.1 (314.95) 44.54 (21.10) 36.4
2009 41.1 (6.00) 25.37 (5.97) 57.9 (19.04) 611.01 (249.98)*a 314.3 (195.75) 51.53 (19.63) 25.92
2010 40.4 (7.67) 25.5 (4.00) 65.46 (19.18) 658.38 (296.37)**a 319.2 (241.88) 50.49 (18.23) 13.78*****b
2011 (ExAblate 2100) 39.47 (6.53) 23.41 (4.25) 61.02 (17.13) 655.06 (257.49)***a 305.12 (203.43) 54.78 (19.01)****a 17.1
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describe and reflect the evolution which has occurred in
patient selection and non-perfused volumes since the
introduction of the technology.
We have found an overall improvement in the NPV
achieved since the introduction of MRgFUS, and the
mean NPV achieved so far with the ExAblate 2100 sys-
tem (54.92%) is the highest in our unit. However, when
compared with the mean NPV achieved with the previ-
ous system the year before (50.49%), this was not found
to be a significant overall improvement. It is possible
that the year-on-year difference in NPV from 2003 to
2010 is a reflection of the increasing experience with the
MRgFUS procedure and treatment apparatus, and that a
similar curve of improvement aided by familiarity with
the technology and better patient selection will continue
to evolve. This increase in experience will inform future
research directions in this area. Recent publications have
reported a 54% NPV following prolonged experience
with the ExAblate 2000 system [4]. A survey of MRgFUS
operators found a target percentage NPV of 76% and a
reported achieved NPV of 58% [6].
The year-on-year results do suggest that patient selection
for MRgFUS has favored women with smaller uteri,
smaller overall fibroid bulk, and a tendency to treat women
with fewer hyper-intense fibroids. There is a known re-
duced efficacy of this treatment in patients with hyper-
intense fibroids on T2-weighted MR imaging [2]. As such,
a tendency towards treating single hypo-intense fibroids,
rather than multiple fibroids or single hyper-intense fi-
broids, has become evident since the introduction of
the technique in 2003, while patient demographic data
remain largely unchanged between the two groups. The
higher non-perfused volumes achieved with the earlier
ExAblate 2000 technology in hypo-intense fibroids in
recent years would seemingly support the rationale for
this shift in patient selection. The initial experience with
the ExAblate 2100 system suggests that we are able to
achieve greater treatment volumes even in those women
with hyper-intense fibroids.
The safety of the newer ExAblate 2100 system has
proven to be encouraging, with no adverse events re-
corded at present. There were no complications experi-
enced using the new system. In particular, there were no
skin burns or evidence of neurologic injury, which were
the two most significant complications seen (albeit very
rarely) using the ExAblate 2000 system. It is perhaps
worth noting that the complications experienced using
either the ExAblate 2000 or ExAblate 2100 were, when
compared to the reported complication profile of hys-
terectomy or myomectomy, relatively modest [7].
As with the introduction of any new technology, a lear-
ning curve aided by experience and familiarity with the
system is to be reasonably expected. We would hope thatonce operators using the new ExAblate 2100 system gain
more experience with this system, the trajectory of NPV
improvement should show further positive improvement.
A more evidence-based approach to patient selection, fa-
voring patients with smaller, less numerous, hypo-intense
fibroids may augment this anticipated process of improve-
ment. Longer follow-up of these patients is required to de-
termine if increases in non-perfused volume in these
patients translate to higher patient satisfaction and a re-
duced re-intervention rate.
Conclusions
Overall, the new ExAblate 2100 system has thus far
shown an encouraging safety record and an improve-
ment in non-perfused volumes achieved, especially in
hyper-intense fibroids.
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